Please assess the completion status of the following clinical trial:

Trial Title: Effects of Cerebral Protection With Filters vs. Flow Reversal on Cerebral Embolization After Carotid Artery Stenting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is at least 18 years old;~2. Patient is willing and capable of complying with the study protocol requirements, including the specified follow-up period;~3. Patient is willing to provide written informed consent prior to enrollment in the study;~4. Male, infertile female, or non-lactating female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7-days prior to study procedure;~5. Patient is either symptomatic, i.e. with a history of TIAs or non-disabling stroke within 6 months of the procedure, with carotid stenosis ≥ 50%, or asymptomatic with carotid stenosis ≥ 80%, as diagnosed by angiography using NASCET methodology;4~6. The target lesion is located in the internal carotid artery (ICA) and the reference vessel diameter, i.e. the common carotid artery (CCA) is \< 10 mm based on angiographic assessment.~Exclusion Criteria:~1. Acute evolving or recent stroke within 7 days of study evaluation;~2. Cardiac embolism;~3. Acute myocardial infarction less than 72 hours prior to the procedure;~4. Major surgical procedure within 30 days preceding CAS;~5. Major surgical procedure within 30 days after the index procedure;~6. Prior major ipsilateral stroke with residual deficit or other neurologic conditions that may affect neurological assessments;~7. Pregnancy or breastfeeding;~8. Severe chronic renal insufficiency (serum creatinine is ≥ 2.5 mg/dL);~9. Contraindication to study medications, including antiplatelet therapy;~10. Prior sensitivity to contrast media that cannot adequately be controlled with pre-medication;~11. Untreatable bleeding diathesis or hypercoagulable state or refusal to blood transfusions;~12. History of uncontrolled pulmonary hypertension;~13. Intracranial pathology;~14. Patient unable or unwilling to undergo DW-MRI of the brain~15. Patient without adequate transtemporal window for transcranial Doppler examination~16. Other anatomic or co-morbid conditions that, in the investigator's opinion, could limit the patient's ability to participate in the study or to comply with follow-up requirements, or impact the scientific soundness of the study results.~17. Isolated ipsilateral hemisphere leading to subject intolerance to flow reversal;~18. Anatomic conditions that preclude performance of carotid artery stenting.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carotid filter (Type: ACTIVE_COMPARATOR): For this intervention group, patients will receive FDA-approved filter devices for cerebral embolic protection during carotid artery stenting intervention.
- Carotid reversal of flow (Type: ACTIVE_COMPARATOR): For this intervention group, patients will receive reversal of flow with the FDA-approved Gore Neuroprotection System for cerebral protection during carotid artery stenting.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy